<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794087</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2022002024</org_study_id>
    <secondary_id>R01ES004738</secondary_id>
    <nct_id>NCT05794087</nct_id>
  </id_info>
  <brief_title>The Role of Macrophage Activation in Lung Injury Following Ozone Exposure</brief_title>
  <official_title>Activated Macrophages and Ozone Toxicity II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to better understand the mechanisms of lung injury from ozone&#xD;
      exposure. Subjects will participate in two exposure sessions: filtered air and 0.2 ppm ozone.&#xD;
      The exposure visits will be at least 2 weeks apart. Subjects will be asked to produce sputum&#xD;
      through coughing after each exposure. The samples will be analyzed for macrophage activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be asked to come to the Rutgers EOHSI clinical center (Piscataway, NJ) for 5&#xD;
      study visits. A physical exam to determine eligibility will be done at the first study visit.&#xD;
      If the subject is healthy and able to produce a sputum sample, he/she will then be scheduled&#xD;
      for 2 3-hour exposure visits, at least 2 weeks apart. One exposure will be to clean air and&#xD;
      the other exposure will be to 0.2 ppm ozone. During the exposures, subjects will be requested&#xD;
      to ride an exercise bicycle intermittently (approximately every 15 minutes). A follow-up&#xD;
      visit for sputum collection will be scheduled either 24, 48, or 72 hours after each exposure&#xD;
      visit. Blood and exhaled breath samples will also be collected at each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2023</start_date>
  <completion_date type="Anticipated">June 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomly assigned to either clean air or ozone for the first exposure then crossed over to the alternate arm for the second exposure.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Subjects and laboratory personnel will not be informed of the type of exposure.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic activity of inflammatory cells in induced sputum</measure>
    <time_frame>Within 3 days of exposure</time_frame>
    <description>The metabolic activity of inflammatory cells in sputum will be assessed by the measurement of ATP production. The measurement will be made on an Agilent Seahorse using a Mitoplate Assay.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Air Pollution</condition>
  <arm_group>
    <arm_group_label>Clean Air, Then Ozone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be exposed to clean air for 3 hours at the first exposure visit and 0.2ppm ozone for 3 hours at the second exposure visit. The visits will be at least 2 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ozone, Then Clean Air</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be exposed to 0.2 ppm ozone for 3 hours at the first exposure visit and clean air for 3 hours at the second exposure visit. The visits will be at least 2 weeks apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clean Air</intervention_name>
    <description>Subjects will have the clean air exposure first, followed by the ozone exposure.</description>
    <arm_group_label>Clean Air, Then Ozone</arm_group_label>
    <arm_group_label>Ozone, Then Clean Air</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ozone</intervention_name>
    <description>Subjects will have the ozone exposure first, followed by the clean air exposure.</description>
    <arm_group_label>Clean Air, Then Ozone</arm_group_label>
    <arm_group_label>Ozone, Then Clean Air</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Vaccinated against COVID-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiovascular disease&#xD;
&#xD;
          -  Respiratory disease&#xD;
&#xD;
          -  Recent (within 4 weeks) respiratory or COVID-19 symptoms&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  HIV Infection&#xD;
&#xD;
          -  History of smoking within the past 5 years.&#xD;
&#xD;
          -  Orthopedic or rheumatologic conditions which would interfere with cycle use&#xD;
&#xD;
          -  Inability to produce a sputum plug at screening&#xD;
&#xD;
          -  Daily use of antioxidant supplements, excluding those in a multivitamin. These&#xD;
             supplements include Vitamin C or E, selenium, beta-carotene, lycopene, lutein,&#xD;
             zeaxanthin and ginkgo biloba. Supplements taken less frequently but at least once a&#xD;
             week will be reviewed by the principal investigator for eligibility determination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard M Kipen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers School of Public Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen Black, PhD</last_name>
    <phone>8484456049</phone>
    <email>kgblack@eohsi.rutgers.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adriana De Resende</last_name>
    <phone>848-445-0178</phone>
    <email>ad998@eohsi.rutgers.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rutgers - EOHSI</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Black, PhD</last_name>
      <phone>848-445-6049</phone>
      <email>kgblack@eohsi.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adriana De Resende</last_name>
      <phone>848-445-0178</phone>
      <email>ad998@eohsi.rutgers.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>February 10, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Howard M. Kipen, MD, MPH</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Macrophage</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

